Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : GC Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The agreement will bring to GC Biopharma 3 programs, including MarzAA (marzeptacog alfa), an engineered factor VIIa which is ready for Phase 3 clinical stage development.
Product Name : MarzAA
Product Type : Protein
Upfront Cash : Undisclosed
February 27, 2023
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : GC Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : CB 2782-PEG
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Vertex Pharmaceuticals
Deal Size : $60.0 million
Deal Type : Agreement
Catalyst Biosciences Sells Complement Portfolio for $60 Million
Details : Companies have signed agreement under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG.
Product Name : CB 2782-PEG
Product Type : Other Small Molecule
Upfront Cash : $60.0 million
May 23, 2022
Lead Product(s) : CB 2782-PEG
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Vertex Pharmaceuticals
Deal Size : $60.0 million
Deal Type : Agreement
Lead Product(s) : CB 2782-PEG
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.
Product Name : CB 2782-PEG
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 15, 2022
Lead Product(s) : CB 2782-PEG
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CB 2782-PEG
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The patent protects nucleic acids encoding modified proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, Catalyst's potential best-in-class treatment for dry AMD, currently licensed to Biogen.
Product Name : CB 2782-PEG
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2021
Lead Product(s) : CB 2782-PEG
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Marzeptacog alfa (activated), or MarzAA demonstrates its potential in treating multiple rare bleeding disorders. MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding.
Product Name : MarzAA
Product Type : Protein
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of the study was to conduct simulations using a MarzAA-specific, population pharmacokinetic (PK) model in a large population following different dose levels of MarzAA.
Product Name : MarzAA
Product Type : Protein
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This trial is being conducted in parallel with the ongoing Phase 3 registration trial evaluating MarzAA for the treatment of episodic bleeds in patients with Hemophilia A or B with inhibitors.
Product Name : MarzAA
Product Type : Protein
Upfront Cash : Inapplicable
June 28, 2021
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB 4332
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs
Details : The natural history of disease study will follow up and assess these patients for clinical outcomes, biomarkers of complement dysregulation as well as safety and effectiveness of their current treatments in preparation for the clinical development progra...
Product Name : CB 4332
Product Type : Protein
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : CB 4332
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study
Details : The results support the use of SQ MarzAA to treat episodic bleeding. Company to enroll the first patient in its Phase 3 registration trial evaluating the efficacy of SQ MarzAA to treat bleeding events in individuals with hemophilia A or B with inhibitors...
Product Name : MarzAA
Product Type : Protein
Upfront Cash : Inapplicable
October 06, 2020
Lead Product(s) : Marzeptacog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB 2679d-GT
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Data Support Catalyst Biosciences’ Potential Hemophilia B Gene Therapy
Details : The new data include a direct comparison between CB 2679d-GT and the Padua variant in a mouse model of hemophilia B.
Product Name : CB 2679d-GT
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : CB 2679d-GT
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable